: Results from the CHOPIN Phase 2 trial showed significant survival improvements for liver treatment, which may support broader adoption and inclusion in clinical guidelines. Financial Snapshot & Market Performance Google's Finance Data
is currently positioned as a high-growth medical device company, with a consensus "Moderate Buy" or "Strong Buy" rating from Wall Street analysts. The company reached a financial turning point in 2025, recording its first year of net income and record-high revenues. Investment Thesis: Why Buy? buy dcth stock
: Management expects at least $100 million in revenue for fiscal year 2026. Projections suggest the company will return to profitability (estimated EPS of $0.04) by Q2 2026. : Results from the CHOPIN Phase 2 trial